2. Search Result
Search Result
Results for "

H-8

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Inhibitory Antibodies

2

Natural
Products

4

Recombinant Proteins

3

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112465
    H-8 dihydrochloride

    		PKA PKC PKG Neurological Disease Cancer
    H-8 dihydrochloride is a selective Cyclic nucleotide-dependent protein kinase inhibitor. H-8 dihydrochloride potently inhibits cGMP- and cAMP-dependent protein phosphorylation. H-8 dihydrochloride enhances the vasodilatory effect induced by 8-bromo-cAMP (HY-12306A). H-8 dihydrochloride fails to attenuate the vasodilatory effects induced by 8-bromo-cGMP (HY-101379A), atrial natriuretic peptide II, or Sodium nitroprusside (HY-B0564) in rat aorta .
    H-8 dihydrochloride
  • HY-N2411
    Geissoschizine methyl ether
    1 Publications Verification

    		 5-HT Receptor Neurological Disease
    Geissoschizine methyl ether is an orally active, blood-brain barrier permeable alkaloid, and a partial agonist of the 5-HT1A receptor. It can be isolated from Uncaria hook. Geissoschizine methyl ether potently inhibits the binding of [ 3H]8-OH-DPAT to the 5-HT1A receptor in a concentration-dependent manner, with an IC50 of 0.904 μM. It ameliorates isolation-induced increased aggression and reduced sociability in mice. Geissoschizine methyl ether promotes oligodendrocyte differentiation and remyelination in the medial prefrontal cortex of adult mice .
    Geissoschizine methyl ether
  • HY-P99620
    Firivumab

    CT-P22; CT120

    		 Influenza Virus Infection
    Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
    Firivumab
  • HY-117093
    H8-A5

    		HDAC Cancer
    H8-A5 is a novel human histone deacetylase 8 (HDAC8) inhibitor. A highly specific ZBG-based pharmacophore model was developed by incorporating a custom zinc-binding group (ZBG) feature. Pharmacophore-based virtual screening identified three novel HDAC8 inhibitors with low micromolar IC50 values (1.8-1.9 μM). Further studies showed that H8-A5 was more selective for HDAC8 than HDAC1/4 and exhibited antiproliferative activity in MDA-MB-231 cancer cells. Molecular docking and molecular dynamics studies showed that H8-A5 could bind to HDAC8, providing a good starting point for the development of HDAC8 inhibitors for cancer treatment.
    H8-A5
  • HY-RS15996
    ZC3H8 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    ZC3H8 Human Pre-designed siRNA Set A contains three designed siRNAs for ZC3H8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ZC3H8 Human Pre-designed siRNA Set A
    ZC3H8 Human Pre-designed siRNA Set A
  • HY-164123
    Antibiofilm agent-9

    		Bacterial Infection
    Antibiofilm agent-9 (Compound 4) is a pyrrolomycin derivative with antibacterial activity. Antibiofilm agent-9 inhibits Bacillus anthracis with MIC of 0.031 μg/mL. Antibiofilm agent-9 exhibits antibiofilm activity with 84% biofilm inhibition (24 h, 8.0 μg/mL). Antibiofilm agent-9 exhibits a good pharmacokinetic characters in mouse model .
    Antibiofilm agent-9
  • HY-N16910
    3,6-Dimethoxy-8,8-dimethyl-2-phenyl-4H,8H-pyrano[2,3-f]chromen-4-one

    		Drug Derivative Others
    3,6-Dimethoxy-8,8-dimethyl-2-phenyl-4H,8H-pyrano[2,3-f]chromen-4-one is a natural flavonoid.
    3,6-Dimethoxy-8,8-dimethyl-2-phenyl-4H,8H-pyrano[2,3-f]chromen-4-one
  • HY-W456337
    (2S,2'S)-2,2'-(1,3,6,8-Tetraoxobenzo[lmn][3,8]phenanthroline-2,7(1H,3H,6H,8H)-diyl)dipropanoic acid

    		MOFs Others
    (2S,2'S)-2,2'-(1,3,6,8-Tetraoxobenzo[lmn][3,8]phenanthroline-2,7(1H,3H,6H,8H)-diyl)dipropanoic acid is a metal-organic framework (MOF).
    (2S,2'S)-2,2'-(1,3,6,8-Tetraoxobenzo[lmn][3,8]phenanthroline-2,7(1H,3H,6H,8H)-diyl)dipropanoic acid
  • HY-180922
    EGFR kinase-IN-8

    		EGFR Akt STAT p38 MAPK Cancer
    EGFR kinase-IN-8 (Compound H8b) is an EGFR inhibitor. EGFR kinase-IN-8 potently inhibits both triple-mutated EGFR L858R/T790M/C797S (IC50 = 3.86 nM) and double-mutated EGFR L858R/T790M (IC50 = 1.23 nM). EGFR kinase-IN-8 suppresses EGFR phosphorylation and downstream AKT, STAT3, and MAPK signaling. EGFR kinase-IN-8 exhibits anticancer activity against non-small cell lung cancer .
    EGFR kinase-IN-8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: